Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 109 |
| Active Pipeline (Recruiting Now) | 50 (36) |
| Completed vs Stopped Early | 36 / 23 (21.1%) |
| Median Closed Actual Enrollment | 27 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| UCSF Medical Center and Helen Diller Cancer Center | San Francisco, CA | 75 |
| Huntsman Cancer Institute at University of Utah | Salt Lake City, UT | 6 |
| Duke University Medical Center | Durham, NC | 6 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06861244 | Embryonal Tumor With Multilayered Rosettes | Phase II | RECRUITING |
| NCT07226453 | Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma | Phase II | RECRUITING |
| NCT05009992 | Combination Therapy for the Treatment of Diffuse Midline Gliomas | Phase II | RECRUITING |
| NCT07110246 | Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas | Phase II | RECRUITING |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for UCSF Health across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the UCSF Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.